PAR Stock Overview
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia.
Paradigm Biopharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.14|
|52 Week High||AU$2.69|
|52 Week Low||AU$0.85|
|1 Month Change||91.07%|
|3 Month Change||75.41%|
|1 Year Change||11.17%|
|3 Year Change||50.18%|
|5 Year Change||692.59%|
|Change since IPO||478.38%|
Recent News & Updates
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|PAR||AU Biotechs||AU Market|
Return vs Industry: PAR exceeded the Australian Biotechs industry which returned -1.3% over the past year.
Return vs Market: PAR exceeded the Australian Market which returned -8% over the past year.
|PAR Average Weekly Movement||12.3%|
|Biotechs Industry Average Movement||11.7%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.6%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: PAR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: PAR's weekly volatility (12%) has been stable over the past year.
About the Company
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Paradigm Biopharmaceuticals Fundamentals Summary
|PAR fundamental statistics|
Is PAR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAR income statement (TTM)|
|Cost of Revenue||AU$169.79k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||-61,675.63%|
How did PAR perform over the long term?See historical performance and comparison
Is PAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PAR?
Other financial metrics that can be useful for relative valuation.
|What is PAR's n/a Ratio?|
Price to Book Ratio vs Peers
How does PAR's PB Ratio compare to its peers?
|PAR PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
PAR Paradigm Biopharmaceuticals
Price-To-Book vs Peers: PAR is expensive based on its Price-To-Book Ratio (9.5x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does PAR's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Book vs Industry: PAR is expensive based on its Price-To-Book Ratio (9.5x) compared to the Australian Biotechs industry average (3x)
Price to Book Ratio vs Fair Ratio
What is PAR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||9.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate PAR's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PAR (A$2.14) is trading above our estimate of fair value (A$0.29)
Significantly Below Fair Value: PAR is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Paradigm Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PAR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PAR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PAR is forecast to have no revenue next year.
High Growth Revenue: PAR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PAR is forecast to be unprofitable in 3 years.
Discover growth companies
How has Paradigm Biopharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAR is currently unprofitable.
Growing Profit Margin: PAR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAR is unprofitable, and losses have increased over the past 5 years at a rate of 45.8% per year.
Accelerating Growth: Unable to compare PAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: PAR has a negative Return on Equity (-76.63%), as it is currently unprofitable.
Discover strong past performing companies
How is Paradigm Biopharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PAR's short term assets (A$63.9M) exceed its short term liabilities (A$14.0M).
Long Term Liabilities: PAR's short term assets (A$63.9M) exceed its long term liabilities (A$613.7K).
Debt to Equity History and Analysis
Debt Level: PAR is debt free.
Reducing Debt: PAR has no debt compared to 5 years ago when its debt to equity ratio was 0%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.9% each year
Discover healthy companies
What is Paradigm Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PAR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Marco Polizzi has been an Executive Vice President of Commercial Operations at Casper Pharma LLC since May 23, 2016. Mr. Polizzi served as the Head of Sales & Marketing, Institutional at Sandoz Pharmac...
Experienced Management: PAR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: PAR's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Paradigm Biopharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Paradigm Biopharmaceuticals Limited
- Ticker: PAR
- Exchange: ASX
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$446.245m
- Shares outstanding: 234.25m
- Website: https://www.paradigmbiopharma.com
- Paradigm Biopharmaceuticals Limited
- 500 Collins Street
- Level 15
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.